A Major Shift in Prostate Cancer Treatment

One of the studies whose results were announced at the ASCO 2015 meeting that most caught our attention was RTOG 0521. This study showed that administering chemotherapy early to patients with locally advanced or high-risk localized prostate cancer significantly increases survival.
Locally advanced or high-risk localized prostate cancers are prostate cancer groups with an unfavorable disease course (poor prognosis). Standard treatment for prostate cancer at this stage consists of radiotherapy and long-term (2-3 years) hormonal therapy. When the RTOG study was planned, its aim was to determine whether earlier use of docetaxel, a chemotherapy drug used in metastatic and hormone-resistant, that is, advanced prostate cancer, would offer any benefit.
High-risk prostate cancer refers to patients with T stage 2c or higher, a Gleason score of 8 –10, or PSA >20.
In this study, 612 patients were enrolled and followed for 6 years. Patients were divided into 2 groups: one received standard treatment with radiotherapy and hormonal therapy; the other received radiotherapy and hormonal therapy plus chemotherapy starting 4 weeks after radiotherapy ended, consisting of 6 cycles of docetaxel.
In conclusion,, adding docetaxel to standard treatment increased 4-year survival from %86 to %93 and reduced the risk of death from all causes by %51. Thus, for the first time, a well-tolerated chemotherapy produced a significant survival increase in localized, high-risk, hormone-sensitive prostate cancer. In summary, this study has changed prostate cancer treatment standards, and chemotherapy, when planning treatment for patients with locally advanced or high-risk localized prostate cancer, should be considered early .
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.